Antigen-based vs. Systemic immunomodulation in type 1 diabetes: The pros and cons

Islets

Volumn 5, Issue 2, 2013, Pages 53-66

  Robert, Sofie ^a   Korf, Hannelie ^a   Gysemans, Conny ^a   Mathieu, Chantal ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Ag specific; Clinical trial; Combination therapy; Patient; Systemic; Therapy; Type 1 diabetes

Indexed keywords

ABATACEPT; ANTIGEN; CYCLOSPORIN A; INSULIN; OTELIXIZUMAB; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TEPLIZUMAB; VITAMIN D;

ANTIGEN BASED IMMUNOMODULATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CONTINUOUS INFUSION; DRUG EFFICACY; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; REVIEW; SYSTEMIC IMMUNOMODULATION;

AG-SPECIFIC; CLINICAL TRIAL; COMBINATION THERAPY; PATIENT; SYSTEMIC; THERAPY; TYPE 1 DIABETES;

ANIMALS; AUTOANTIGENS; AUTOIMMUNITY; DIABETES MELLITUS, TYPE 1; HUMANS; IMMUNOMODULATION; IMMUNOSUPPRESSION; IMMUNOTHERAPY, ACTIVE; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84879332708     PISSN: 19382014     EISSN: 19382022     Source Type: Journal    
DOI: 10.4161/isl.24785     Document Type: Review

References (149)

1. Patterson CC, Dahlquist GG, Gyürüs E, Green A, Soltész G; EURODIAB Study Group. Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study. Lancet 2009; 373:2027-33; PMID:19481249; http://dx.doi.org/10.1016/S0140-6736(09)60568-7
2. Lehuen A, Diana J, Zaccone P, Cooke A. Immune cell crosstalk in type 1 diabetes. Nat Rev Immunol 2010; 10:501-13; PMID:20577267; http://dx.doi.org/10. 1038/nri2787
3. The Canadian-European Randomized Control Trial Group. Cyclosporin-induced remission of IDDM after early intervention. Association of 1 yr of cyclosporin treatment with enhanced insulin secretion. Diabetes 1988; 37:1574-82; PMID:2903105; http://dx.doi.org/10.2337/diabetes.37.11.1574
4. Feutren G, Papoz L, Assan R, Vialettes B, Karsenty G, Vexiau P, et al. Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial. Lancet 1986; 2:119-24; PMID:2873396; http://dx.doi.org/10.1016/S0140-6736(86)91943-4
5. Bougneres P F, Carel JC, Castano L, Boitard C, Gardin J P, Landais P, et al. Factors associated with early remission of type I diabetes in children treated with cyclosporine. N Engl J Med 1988; 318:663-70; PMID:3125434; http://dx.doi.org/10.1056/NEJM198803173181103 (Pubitemid 18083606)
6. Herold KC, Gitelman SE, Masharani U, Hagopian W, Bisikirska B, Donaldson D, et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005; 54:1763-9; PMID:15919798; http://dx.doi.org/10.2337/diabe-tes.54.6.1763 (Pubitemid 40770766)
7. Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005; 352:2598-608; PMID:15972866; http://dx.doi.org/10.1056/ NEJMoa043980 (Pubitemid 41007846)
8. Sherry N, Hagopian W, Ludvigsson J, Jain SM, Wahlen J, Ferry RJ Jr., et al.; Protégé Trial Investigators. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet 2011; 378:487-97; PMID:21719095; http://dx.doi.org/10.1016/S0140-6736(11)60931-8
9. Pickersgill LM, Mandrup-Poulsen TR. The anti-inter-leukin-1 in type 1 diabetes action trial - background and rationale. Diabetes Metab Res Rev 2009; 25:321-4; PMID:19405081; http://dx.doi.org/10.1002/dmrr.960
10. Orban T, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, et al.; Type 1 Diabetes TrialNet Abatacept Study Group. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 2011; 378:412-9; PMID:21719096; http://dx.doi.org/10.1016/S0140-6736(11)60886-6
11. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, Goland R, et al.; Type 1 Diabetes TrialNet Anti-CD20 Study Group. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009; 361:2143-52; PMID:19940299; http://dx.doi.org/10.1056/NEJMoa0904452
12. Walter M, Kaupper T, Adler K, Foersch J, Bonifacio E, Ziegler AG. No effect of the 1alpha,25-dihydroxyvi-tamin D3 on beta-cell residual function and insulin requirement in adults with new-onset type 1 diabetes. Diabetes Care 2010; 33:1443-8; PMID:20357369; http://dx.doi.org/10.2337/dc09-2297
13. Pitocco D, Crinò A, Di Stasio E, Manfrini S, Guglielmi C, Spera S, et al.; IMDIAB Group. The effects of calcitriol and nicotinamide on residual pancreatic beta-cell function in patients with recent-onset Type 1 diabetes (IMDIAB XI). Diabet Med 2006; 23:920-3; PMID:16911633; http://dx.doi.org/10. 1111/j.1464-5491.2006.01921.x (Pubitemid 44141083)
14. Li X, Liao L, Yan X, Huang G, Lin J, Lei M, et al. Protective effects of 1-alpha-hydroxyvitamin D3 on residual beta-cell function in patients with adult-onset latent autoimmune diabetes (LADA). Diabetes Metab Res Rev 2009; 25:411-6; PMID:19488999; http://dx.doi.org/10.1002/dmrr.977
15. Bock G, Prietl B, Mader JK, Höller E, Wolf M, Pilz S, et al. The effect of vitamin D supplementation on peripheral regulatory T cells and β cell function in healthy humans: a randomized controlled trial. Diabetes Metab Res Rev 2011; 27:942-5; PMID:22069289; http://dx.doi.org/10.1002/dmrr.1276
16. Tedesco D, Haragsim L. Cyclosporine: a review. J Transplant 2012; 2012:230-386; PMID:22263104; http://dx.doi.org/10.1155/2012/230-386
17. Laupacis A, Stiller CR, Gardell C, Keown P, Dupre J, Wallace AC, et al. Cyclosporin prevents diabetes in BB Wistar rats. Lancet 1983; 1:10-2; PMID:6129365; http://dx.doi.org/10.1016/S0140-6736(83)91558-1 (Pubitemid 13211278)
18. Stiller CR, Dupré J, Gent M, Jenner MR, Keown PA, Laupacis A, et al. Effects of cyclosporine immunosup-pression in insulin-dependent diabetes mellitus of recent onset. Science 1984; 223:1362-7; PMID:6367043; http://dx.doi.org/10.1126/science.6367043 (Pubitemid 14161003)
19. Dupré J, Stiller CR, Gent M, Donner A, von Graffenreid B, Murphy G, et al. Effects of immuno-suppression with cyclosporine in insulin-dependent diabetes mellitus of recent onset: the Canadian open study at 44 months. Transplant Proc 1988; 20(Suppl 4):184-92; PMID:3289204
20. Martin S, Schernthaner G, Nerup J, Gries FA, Koivisto VA, Dupré J, et al. Follow-up of cyclosporin A treatment in type 1 (insulin-dependent) diabetes mellitus: lack of long-term effects. Diabetologia 1991; 34:429-34; PMID:1884902; http://dx.doi.org/10.1007/BF00403182
21. Bougnères P F, Landais P, Boisson C, Carel JC, Frament N, Boitard C, et al. Limited duration of remission of insulin dependency in children with recent overt type I diabetes treated with low-dose cyclosporin. Diabetes 1990; 39:1264-72; PMID:2210078; http://dx.doi.org/10.2337/diabetes.39.10.1264 (Pubitemid 20327064)
22. Parving HH, Tarnow L, Nielsen FS, Rossing P, Mandrup-Poulsen T, Osterby R, et al. Cyclosporine nephrotoxicity in type 1 diabetic patients. A 7-year follow-up study. Diabetes Care 1999; 22:478-83; PMID:10097932; http://dx.doi.org/10.2337/dia-care.22.3.478 (Pubitemid 29106908)
23. Assan R, Blanchet F, Feutren G, Timsit J, Larger E, Boitard C, et al. Normal renal function 8 to 13 years after cyclosporin A therapy in 285 diabetic patients. Diabetes Metab Res Rev 2002; 18:464-72; PMID:12469360; http://dx.doi.org/10.1002/dmrr.325 (Pubitemid 36041601)
24. Cosimi AB, Burton RC, Colvin RB, Goldstein G, Delmonico FL, LaQuaglia M P, et al. Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation 1981; 32:535-9; PMID:7041358; http://dx.doi.org/10. 1097/00007890-198112000-00018 (Pubitemid 12204717)
25. Alegre ML, Tso JY, Sattar HA, Smith J, Desalle F, Cole M, et al. An anti-murine CD3 monoclonal antibody with a low affinity for Fc gamma receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity. J Immunol 1995; 155:1544-55; PMID:7636216
26. Ferran C, Sheehan K, Dy M, Schreiber R, Merite S, Landais P, et al. Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: further evidence for transient in vivo T cell activation. Eur J Immunol 1990; 20:509-15; PMID:2138557; http://dx.doi.org/10.1002/eji.1830200308 (Pubitemid 20101288)
27. Vossen AC, Tibbe GJ, Kroos MJ, van de Winkel JG, Benner R, Savelkoul H F. Fc receptor binding of anti-CD3 monoclonal antibodies is not essential for immunosuppression, but triggers cytokine-related side effects. Eur J Immunol 1995; 25:1492-6; PMID:7614975; http://dx.doi.org/10.1002/eji.1830250603
28. Xu D, Alegre ML, Varga SS, Rothermel AL, Collins AM, Pulito VL, et al. In vitro characterization of five humanized OKT3 effector function variant antibodies. Cell Immunol 2000; 200:16-26; PMID:10716879; http://dx.doi.org/10. 1006/cimm.2000.1617 (Pubitemid 30170076)
29. Bolt S, Routledge E, Lloyd I, Chatenoud L, Pope H, Gorman SD, et al. The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur J Immunol 1993; 23:403-11; PMID:8436176; http://dx.doi.org/10.1002/eji.1830230216 (Pubitemid 23075070)
30. Chatenoud L, Primo J, Bach J F. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol 1997; 158:2947-54; PMID:9058834 (Pubitemid 127470558)
31. Chatenoud L, Thervet E, Primo J, Bach J F. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci U S A 1994; 91:123-7; PMID:8278351; http://dx.doi.org/10.1073/pnas.91. 1.123 (Pubitemid 24018655)
32. Penaranda C, Tang Q, Bluestone JA. Anti-CD3 therapy promotes tolerance by selectively depleting pathogenic cells while preserving regulatory T cells. J Immunol 2011; 187:2015-22; PMID:21742976; http://dx.doi.org/10.4049/jimmunol. 1100713
33. Chatenoud L, Bluestone JA. CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol 2007; 7:622-32; PMID:17641665; http://dx.doi.org/10.1038/nri2134 (Pubitemid 47123550)
34. Chatenoud L, Baudrihaye M F, Kreis H, Goldstein G, Schindler J, Bach J F. Human in vivo antigenic modulation induced by the anti-T cell OKT3 monoclonal antibody. Eur J Immunol 1982; 12:979-82; PMID:6759145; http://dx.doi.org/10. 1002/eji.1830121116 (Pubitemid 13203591)
35. Nishio J, Feuerer M, Wong J, Mathis D, Benoist C. Anti-CD3 therapy permits regulatory T cells to surmount T cell receptor-specified peripheral niche constraints. J Exp Med 2010; 207:1879-89; PMID:20679403; http://dx.doi.org/10.1084/jem.20100205
36. Belghith M, Bluestone JA, Barriot S, Mégret J, Bach J F, Chatenoud L. TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med 2003; 9:1202-8; PMID:12937416; http://dx.doi.org/10.1038/nm924 (Pubitemid 37173706)
37. You S, Leforban B, Garcia C, Bach J F, Bluestone JA, Chatenoud L. Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment. Proc Natl Acad Sci U S A 2007; 104:6335-40; PMID:17389382; http://dx.doi.org/10.1073/pnas.0701171104 (Pubitemid 47186095)
38. Waldron-Lynch F, Henegariu O, Deng S, Preston-Hurlburt P, Tooley J, Flavell R, et al. Teplizumab induces human gut-tropic regulatory cells in humanized mice and patients. Sci Transl Med 2012; 4:18ra12; PMID:22277969; http://dx.doi.org/10.1126/scitrans-lmed.3003401
39. Kuhn C, You S, Valette F, Hale G, van Endert P, Bach J F, et al. Human CD3 transgenic mice: preclinical testing of antibodies promoting immune tolerance. Sci Transl Med 2011; 3:68ra10; PMID:21289272; http://dx.doi.org/10. 1126/scitranslmed.3001830
40. Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002; 346:1692-8; PMID:12037148; http://dx.doi.org/10.1056/ NEJMoa012864 (Pubitemid 34547482)
41. Herold KC, Gitelman S, Greenbaum C, Puck J, Hagopian W, Gottlieb P, et al.; Immune Tolerance Network ITN007AI Study Group. Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin Immunol 2009; 132:166-73; PMID:19443276; http://dx.doi.org/10.1016/j.clim.2009.04.007
42. Keymeulen B, Walter M, Mathieu C, Kaufman L, Gorus F, Hilbrands R, et al. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia 2010; 53:614-23; PMID:20225393; http://dx.doi.org/10.1007/s00125-009-1644-9
43. Keymeulen B, Candon S, Fafi-Kremer S, Ziegler A, Leruez-Ville M, Mathieu C, et al. Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients. Blood 2010; 115:1145-55; PMID:20007541; http://dx.doi.org/10.1182/blood-2009-02-204875
44. Alkemade GM, Hilbrands R, Vandemeulebroucke E, Pipeleers D, Waldmann H, Mathieu C, et al. Preservation of recall immunity in anti-CD3-treated recent onset type 1 diabetes patients. Diabetes Metab Res Rev 2011; 27:925-7; PMID:22069286; http://dx.doi.org/10.1002/dmrr.1273
45. Mandrup-Poulsen T, Bendtzen K, Nerup J, Dinarello CA, Svenson M, Nielsen JH. Affinity-purified human interleukin I is cytotoxic to isolated islets of Langerhans. Diabetologia 1986; 29:63-7; PMID:3514344; http://dx.doi.org/10.1007/ BF02427283 (Pubitemid 16162744)
46. Eizirik DL, Mandrup-Poulsen T. A choice of death - the signal-transduction of immune-mediated beta-cell apoptosis. Diabetologia 2001; 44:2115-33; PMID:11793013; http://dx.doi.org/10.1007/s001250100021 (Pubitemid 34015464)
47. Larsen CM, Faulenbach M, Vaag A, Ehses JA, Donath MY, Mandrup-Poulsen T. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 2009; 32:1663-8; PMID:19542207; http://dx.doi.org/10. 2337/dc09-0533
48. Nuki G, Bresnihan B, Bear MB, McCabe D; European Group Of Clinical Investigators. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46:2838-46; PMID:12428223; http://dx.doi.org/10.1002/art.10578 (Pubitemid 35315874)
49. Moran A, Bundy B, Becker DJ, Dimeglio LA, Gitelman SE, Goland R, et al.; for the Type 1 Diabetes TrialNet Canakinumab Study Group; for the AIDA Study Group. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet 2013; 381:1905-15;PMID:23562090; http://dx.doi.org/10.1016/S0140-6736(13)60023-9
50. Rudd CE, Taylor A, Schneider H. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev 2009; 229:12-26; PMID:19426212; http://dx.doi.org/10.1111/j.1600-065X.2009.00770.x.
51. Linsley PS, Nadler SG. The clinical utility of inhibiting CD28-mediated costimulation. Immunol Rev 2009; 229:307-21; PMID:19426230; http://dx.doi.org/ 10.1111/j.1600-065X.2009.00780.x
52. Abrams JR, Lebwohl MG, Guzzo CA, Jegasothy BV, Goldfarb M T, Goffe BS, et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999; 103:1243-52; PMID:10225967; http://dx.doi.org/10.1172/JCI5857 (Pubitemid 29218294)
53. Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003; 349:1907-15; PMID:14614165; http://dx.doi.org/10.1056/NEJMoa035075 (Pubitemid 37409707)
54. Lenschow DJ, Ho SC, Sattar H, Rhee L, Gray G, Nabavi N, et al. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J Exp Med 1995; 181:1145-55; PMID:7532678; http://dx.doi.org/10.1084/jem.181.3.1145
55. Larsen C P, Pearson TC, Adams AB, Tso P, Shirasugi N, Strobert E, et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005; 5:443-53; PMID:15707398; http://dx.doi.org/10.1111/j.1600-6143.2005.00749.x (Pubitemid 40313335)
56. Martin S, Wolf-Eichbaum D, Duinkerken G, Scherbaum WA, Kolb H, Noordzij JG, et al. Development of type 1 diabetes despite severe hereditary B-lymphocyte deficiency. N Engl J Med 2001; 345:1036-40; PMID:11586956; http://dx.doi.org/ 10.1056/NEJMoa010465
57. Hu CY, Rodriguez-Pinto D, Du W, Ahuja A, Henegariu O, Wong FS, et al. Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J Clin Invest 2007; 117:3857-67; PMID:18060033; http://dx.doi.org/10. 1172/JCI32405 (Pubitemid 350224095)
58. Mathieu C, Badenhoop K. Vitamin D and type 1 diabetes mellitus: state of the art. Trends Endocrinol Metab 2005; 16:261-6; PMID:15996876; http://dx.doi.org/10.1016/j.tem.2005.06.004 (Pubitemid 41058757)
59. Mathieu C, Waer M, Laureys J, Rutgeerts O, Bouillon R. Prevention of autoimmune diabetes in NOD mice by 1,25 dihydroxyvitamin D3. Diabetologia 1994; 37:552-8; PMID:7926338; http://dx.doi.org/10.1007/BF00403372 (Pubitemid 24162425)
60. Gregori S, Giarratana N, Smiroldo S, Uskokovic M, Adorini L. A 1alpha,25-dihydroxyvitamin D(3) analog enhances regulatory T-cells and arrests autoimmune diabetes in NOD mice. Diabetes 2002; 51:1367-74; PMID:11978632; http://dx.doi.org/10.2337/diabe-tes.51.5.1367 (Pubitemid 34826601)
61. Zella JB, McCary LC, DeLuca H F. Oral administration of 1,25-dihydroxyvitamin D3 completely protects NOD mice from insulin-dependent diabetes mellitus. Arch Biochem Biophys 2003; 417:77-80; PMID:12921782; http://dx.doi.org/10.1016/S0003-9861(03)00338-2 (Pubitemid 36960051)
62. Hyppönen E, Läärä E, Reunanen A, Järvelin MR, Virtanen SM. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 2001; 358:1500-3; PMID:11705562; http://dx.doi.org/10.1016/S0140- 6736(01)06580-1 (Pubitemid 33055701)
63. Vitamin D supplement in early childhood and risk for Type I (insulin-dependent) diabetes mellitus. The EURODIAB Substudy 2 Study Group. Diabetologia 1999; 42:51-4; PMID:10027578; http://dx.doi.org/10.1007/ s001250051112 (Pubitemid 29039737)
64. Kang EM, Zickler P P, Burns S, Langemeijer SM, Brenner S, Phang OA, et al. Hematopoietic stem cell transplantation prevents diabetes in NOD mice but does not contribute to significant islet cell regeneration once disease is established. Exp Hematol 2005; 33:699-705; PMID:15911094; http://dx.doi.org/10. 1016/j.exphem.2005.03.008 (Pubitemid 40725836)
65. Voltarelli JC, Couri CE, Stracieri AB, Oliveira MC, Moraes DA, Pieroni F, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2007; 297:1568-76; PMID:17426276; http://dx.doi.org/10.1001/jama.297.14.1568 (Pubitemid 46588370)
66. Couri CE, Oliveira MC, Stracieri AB, Moraes DA, Pieroni F, Barros GM, et al. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2009; 301:1573-9; PMID:19366777; http://dx.doi.org/ 10.1001/jama.2009.470
67. Karges WJ, Ilonen J, Robinson BH, Dosch HM. Self and non-self antigen in diabetic autoimmunity: molecules and mechanisms. Mol Aspects Med 1995; 16:79-213; PMID:7658921; http://dx.doi.org/10.1016/0098-2997(95)00001-W
68. Kawasaki E, Eisenbarth GS. High-throughput radioassays for autoantibodies to recombinant autoantigens. Front Biosci 2000; 5:E181-90; PMID:11056082; http://dx.doi.org/10.2741/kawasaki
69. Long AE, Gooneratne AT, Rokni S, Williams AJ, Bingley PJ. The role of autoantibodies to zinc transporter 8 in prediction of type 1 diabetes in relatives: lessons from the European Nicotinamide Diabetes Intervention Trial (ENDIT) cohort. J Clin Endocrinol Metab 2012; 97:632-7; PMID:22162482
70. Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 2010; 464:1293-300; PMID:20432533; http://dx.doi.org/10.1038/nature08933
71. Knip M, Siljander H. Autoimmune mechanisms in type 1 diabetes. Autoimmun Rev 2008; 7:550-7; PMID:18625444; http://dx.doi.org/10.1016/j.autrev.2008.04.008
72. Orban T, Sosenko JM, Cuthbertson D, Krischer J P, Skyler JS, Jackson R, et al.; Diabetes Prevention Trial-Type 1 Study Group. Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2009; 32:2269-74; PMID:19741189; http://dx.doi.org/10.2337/dc09-0934
73. Di Lorenzo T P, Peakman M, Roep BO. Translational mini-review series on type 1 diabetes: Systematic analysis of T cell epitopes in autoimmune diabetes. Clin Exp Immunol 2007; 148:1-16; PMID:17349009; http://dx.doi.org/10.1111/j. 1365-2249.2006.03244.x (Pubitemid 46364983)
74. Stadinski BD, Delong T, Reisdorph N, Reisdorph R, Powell RL, Armstrong M, et al. Chromogranin A is an autoantigen in type 1 diabetes. Nat Immunol 2010; 11:225-31; PMID:20139986; http://dx.doi.org/10.1038/ni.1844
75. Lieberman SM, Evans AM, Han B, Takaki T, Vinnitskaya Y, Caldwell JA, et al. Identification of the beta cell antigen targeted by a prevalent population of pathogenic CD8+ T cells in autoimmune diabetes. Proc Natl Acad Sci U S A 2003; 100:8384-8; PMID:12815107; http://dx.doi.org/10.1073/pnas.0932778100 (Pubitemid 36842554)
76. Li SW, Koya V, Li Y, Donelan W, Lin P, Reeves WH, et al. Pancreatic duodenal homeobox 1 protein is a novel beta-cell-specific autoantigen for type I diabetes. Lab Invest 2010; 90:31-9; PMID:19901909; http://dx.doi.org/10.1038/ labinvest.2009.116
77. Delong T, Baker RL, Reisdorph N, Reisdorph R, Powell RL, Armstrong M, et al. Islet amyloid polypeptide is a target antigen for diabetogenic CD4+ T cells. Diabetes 2011; 60:2325-30; PMID:21734016; http://dx.doi.org/10.2337/db11-0288
78. Nakayama M. Insulin as a key autoantigen in the development of type 1 diabetes. Diabetes Metab Res Rev 2011; 27:773-7; PMID:22069258; http://dx.doi.org/10.1002/dmrr.1250
79. Moriyama H, Abiru N, Paronen J, Sikora K, Liu E, Miao D, et al. Evidence for a primary islet autoantigen (preproinsulin 1) for insulitis and diabetes in the nonobese diabetic mouse. Proc Natl Acad Sci U S A 2003; 100:10376-81; PMID:12925730; http://dx.doi.org/10.1073/pnas.1834450100 (Pubitemid 37071886)
80. Daniel D, Wegmann DR. Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23). Proc Natl Acad Sci U S A 1996; 93:956-60; PMID:8570667; http://dx.doi.org/10.1073/ pnas.93.2.956 (Pubitemid 26041202)
81. Alleva DG, Crowe PD, Jin L, Kwok WW, Ling N, Gottschalk M, et al. A disease-associated cellular immune response in type 1 diabetics to an immunodominant epitope of insulin. J Clin Invest 2001; 107:173-80; PMID:11160133; http://dx.doi.org/10.1172/JCI8525 (Pubitemid 32096833)
82. Yu L, Robles DT, Abiru N, Kaur P, Rewers M, Kelemen K, et al. Early expression of antiinsulin autoantibodies of humans and the NOD mouse: evidence for early determination of subsequent diabetes. Proc Natl Acad Sci U S A 2000; 97:1701-6; PMID:10677521; http://dx.doi.org/10.1073/pnas.040556697 (Pubitemid 30118506)
83. Jaeckel E, Klein L, Martin-Orozco N, von Boehmer H. Normal incidence of diabetes in NOD mice tolerant to glutamic acid decarboxylase. J Exp Med 2003; 197:1635-44; PMID:12796471; http://dx.doi.org/10.1084/jem.20030215 (Pubitemid 36745339)
84. Kash S F, Condie BG, Baekkeskov S. Glutamate decarboxylase and GABA in pancreatic islets: lessons from knock-out mice. Horm Metab Res 1999; 31:340-4; PMID:10422732; http://dx.doi.org/10.1055/s-2007-978750 (Pubitemid 29299617)
85. Kubosaki A, Miura J, Notkins AL. IA-2 is not required for the development of diabetes in NOD mice. Diabetologia 2004; 47:149-50; PMID:14614561; http://dx.doi.org/10.1007/s00125-003-1252-z (Pubitemid 38141956)
86. Yoon JW, Yoon CS, Lim HW, Huang QQ, Kang Y, Pyun KH, et al. Control of autoimmune diabetes in NOD mice by GAD expression or suppression in beta cells. Science 1999; 284:1183-7; PMID:10325232; http://dx.doi.org/10.1126/science.284. 5417.1183 (Pubitemid 29288411)
87. Tisch R, Yang XD, Singer SM, Liblau RS, Fugger L, McDevitt HO. Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice. Nature 1993; 366:72-5; PMID:8232539; http://dx.doi.org/10.1038/ 366072a0 (Pubitemid 23345239)
88. Kaufman DL, Clare-Salzler M, Tian J, Forsthuber T, Ting GS, Robinson P, et al. Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature 1993; 366:69-72; PMID:7694152; http://dx.doi.org/10.1038/366069a0 (Pubitemid 23345238)
89. Verge C F, Gianani R, Kawasaki E, Yu L, Pietropaolo M, Chase H P, et al. Number of autoantibodies (against insulin, GAD or ICA512/IA2) rather than particular autoantibody specificities determines risk of type I diabetes. J Autoimmun 1996; 9:379-83; PMID:8816974; http://dx.doi.org/10.1006/jaut.1996.0051 (Pubitemid 26226598)
90. Sherr J, Sosenko J, Skyler JS, Herold KC. Prevention of type 1 diabetes: the time has come. Nat Clin Pract Endocrinol Metab 2008; 4:334-43; PMID:18446141 (Pubitemid 351733474)
91. Knip M, Kukko M, Kulmala P, Veijola R, Simell O, Akerblom HK, et al. Humoral beta-cell autoimmunity in relation to HLA-defined disease susceptibility in preclinical and clinical type 1 diabetes. Am J Med Genet 2002; 115:48-54; PMID:12116176; http://dx.doi.org/10.1002/ajmg.10343 (Pubitemid 34650722)
92. You S, Chatenoud L. Proinsulin: a unique autoantigen triggering autoimmune diabetes. J Clin Invest 2006; 116:3108-10; PMID:17143326; http://dx.doi.org/10.1172/JCI30760 (Pubitemid 44878624)
93. Faria AM, Weiner HL. Oral tolerance: therapeutic implications for autoimmune diseases. Clin Dev Immunol 2006; 13:143-57; PMID:17162357; http://dx.doi.org/10.1080/17402520600876804 (Pubitemid 44950033)
94. al-Sabbagh A, Miller A, Santos LM, Weiner HL. Antigen-driven tissue-specific suppression following oral tolerance: orally administered myelin basic protein suppresses proteolipid protein-induced experimental autoimmune encephalomyelitis in the SJL mouse. Eur J Immunol 1994; 24:2104-9; PMID:7522160; http://dx.doi.org/10.1002/eji.1830240926
95. Weiner HL, da Cunha A P, Quintana F, Wu H. Oral tolerance. Immunol Rev 2011; 241:241-59; PMID:21488901; http://dx.doi.org/10.1111/j.1600-065X.2011. 01017.x
96. Tian J, Lehmann PV, Kaufman DL. Determinant spreading of T helper cell 2 (Th2) responses to pancreatic islet autoantigens. J Exp Med 1997; 186:2039-43; PMID:9396773; http://dx.doi.org/10.1084/jem.186.12.2039 (Pubitemid 28013688)
97. Diabetes Prevention Trial - Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002; 346:1685-91; PMID:12037147; http://dx.doi.org/10.1056/NEJMoa012350 (Pubitemid 34547481)
98. Vandemeulebroucke E, Gorus FK, Decochez K, Weets I, Keymeulen B, De Block C, et al.; Belgian Diabetes Registry. Insulin treatment in IA-2A-positive relatives of type 1 diabetic patients. Diabetes Metab 2009; 35:319-27; PMID:19647467; http://dx.doi.org/10.1016/j.diabet.2009.02.005
99. Skyler JS, Krischer J P, Wolfsdorf J, Cowie C, Palmer J P, Greenbaum C, et al. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial - Type 1. Diabetes Care 2005; 28:1068-76; PMID:15855569; http://dx.doi.org/10.2337/diacare.28.5.1068 (Pubitemid 40616615)
100. Carel JC, Landais P, Bougnères P. Therapy to prevent type 1 diabetes mellitus. N Engl J Med 2002; 347:1115-6; PMID:12362017; http://dx.doi.org/10.1056/NEJM200210033471415
101. Chaillous L, Lefèvre H, Thivolet C, Boitard C, Lahlou N, Atlan-Gepner C, et al. Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabète Insuline Orale group. Lancet 2000; 356:545-9; PMID:10950231; http://dx.doi.org/10.1016/S0140-6736(00)02579-4 (Pubitemid 30611859)
102. Pozzilli P, Pitocco D, Visalli N, Cavallo MG, Buzzetti R, Crinò A, et al.; IMDIAB Group. No effect of oral insulin on residual beta-cell function in recentonset type I diabetes (the IMDIAB VII). Diabetologia 2000; 43:1000-4; PMID:10990077; http://dx.doi.org/10.1007/s001250051482 (Pubitemid 30655719)
103. Ergun-Longmire B, Marker J, Zeidler A, Rapaport R, Raskin P, Bode B, et al. Oral insulin therapy to prevent progression of immune-mediated (type 1) diabetes. Ann N Y Acad Sci 2004; 1029:260-77; PMID:15681764; http://dx.doi.org/10.1196/annals.1309.057 (Pubitemid 40298536)
104. Näntö-Salonen K, Kupila A, Simell S, Siljander H, Salonsaari T, Hekkala A, et al. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet 2008; 372:1746-55; PMID:18814906; http://dx.doi.org/10.1016/S0140-6736(08)61309-4
105. Fourlanos S, Perry C, Gellert SA, Martinuzzi E, Mallone R, Butler J, et al. Evidence that nasal insulin induces immune tolerance to insulin in adults with autoimmune diabetes. Diabetes 2011; 60:1237-45; PMID:21307076; http://dx.doi.org/10.2337/db10-1360
106. Agardh CD, Cilio CM, Lethagen A, Lynch K, Leslie RD, Palmér M, et al. Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J Diabetes Complications 2005; 19:238-46; PMID:15993359; http://dx.doi.org/10.1016/j.jdiacomp.2004.12.003 (Pubitemid 40910206)
107. Ludvigsson J, Faresjö M, Hjorth M, Axelsson S, Chéramy M, Pihl M, et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008; 359:1909-20; PMID:18843118; http://dx.doi.org/10. 1056/NEJMoa0804328
108. Wherrett DK, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, et al.; Type 1 Diabetes TrialNet GAD Study Group. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet 2011; 378:319-27; PMID:21714999; http://dx.doi.org/10.1016/S0140-6736(11)60895-7.
109. Ludvigsson J, Krisky D, Casas R, Battelino T, Castaño L, Greening J, et al. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. N Engl J Med 2012; 366:433-42; PMID:22296077; http://dx.doi.org/10.1056/ NEJMoa1107096.
110. Maron R, Guerau-de-Arellano M, Zhang X, Weiner HL. Oral administration of insulin to neonates suppresses spontaneous and cyclophosphamide induced diabetes in the NOD mouse. J Autoimmun 2001; 16:21-8; PMID:11221993; http://dx.doi.org/10.1006/jaut.2000.0471 (Pubitemid 32174171)
111. Zhang ZJ, Davidson L, Eisenbarth G, Weiner HL. Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc Natl Acad Sci U S A 1991; 88:10252-6; PMID:1946445; http://dx.doi.org/10.1073/pnas. 88.22.10252 (Pubitemid 21915813)
112. Prasad S, Kohm A P, McMahon JS, Luo X, Miller SD. Pathogenesis of NOD diabetes is initiated by reactivity to the insulin B chain 9-23 epitope and involves functional epitope spreading. J Autoimmun 2012; 39:347-53; PMID:22647732; http://dx.doi.org/10.1016/j.jaut.2012.04.005
113. Harrison LC, Dempsey-Collier M, Kramer DR, Takahashi K. Aerosol insulin induces regulatory CD8 gamma delta T cells that prevent murine insulin-dependent diabetes. J Exp Med 1996; 184:2167-74; PMID:8976172; http://dx.doi.org/10.1084/ jem.184.6.2167 (Pubitemid 27023717)
114. Every AL, Kramer DR, Mannering SI, Lew AM, Harrison LC. Intranasal vaccination with proinsulin DNA induces regulatory CD4+ T cells that prevent experimental autoimmune diabetes. J Immunol 2006; 176:4608-15; PMID:16585551.
115. Nakayama M, Abiru N, Moriyama H, Babaya N, Liu E, Miao D, et al. Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature 2005; 435:220-3; PMID:15889095; http://dx.doi.org/10.1038/nature03523 (Pubitemid 40685949)
116. Nakayama M, Babaya N, Miao D, Gianani R, Liu E, Elliott J F, et al. Long-term prevention of diabetes and marked suppression of insulin autoantibodies and insulitis in mice lacking native insulin B9-23 sequence. Ann N Y Acad Sci 2006; 1079:122-9; PMID:17130542; http://dx.doi.org/10.1196/annals. 1375.018 (Pubitemid 44968711)
117. Vehik K, Cuthbertson D, Ruhlig H, Schatz DA, Peakman M, Krischer JP; DPT-1 and TrialNet Study Groups. Long-term outcome of individuals treated with oral insulin: diabetes prevention trial-type 1 (DPT-1) oral insulin trial. Diabetes Care 2011; 34:1585-90; PMID:21610124; http://dx.doi.org/10.2337/dc11- 0523
118. Ryhänen SJ, Härkönen T, Siljander H, Näntö- Salonen K, Simell T, Hyöty H, et al. Impact of intranasal insulin on insulin antibody affinity and isotypes in young children with HLA-conferred susceptibility to type 1 diabetes. Diabetes Care 2011; 34:1383-8; PMID:21515841; http://dx.doi.org/10.2337/dc10-1449
119. Orban T, Farkas K, Jalahej H, Kis J, Treszl A, Falk B, et al. Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy. J Autoimmun 2010; 34:408-15; PMID:19931408; http://dx.doi.org/10.1016/j.jaut.2009.10.005
120. Jun HS, Khil LY, Yoon JW. Role of glutamic acid decar-boxylase in the pathogenesis of type 1 diabetes. Cell Mol Life Sci 2002; 59:1892-901; PMID:12530520; http://dx.doi.org/10.1007/PL00012512 (Pubitemid 36015862)
121. Björk E, Kämpe O, Karlsson FA, Pipeleers DG, Andersson A, Hellerström C, et al. Glucose regulation of the autoantigen GAD65 in human pancreatic islets. J Clin Endocrinol Metab 1992; 75:1574-6; PMID:1464667; http://dx.doi.org/10.1210/jc.75.6.1574 (Pubitemid 23001425)
122. Ludvigsson J. Therapy with GAD in diabetes. Diabetes Metab Res Rev 2009; 25:307-15; PMID:19267332; http://dx.doi.org/10.1002/dmrr.941
123. Kanaani J, Lissin D, Kash S F, Baekkeskov S. The hydrophilic isoform of glutamate decarboxylase, GAD67, is targeted to membranes and nerve terminals independent of dimerization with the hydrophobic membrane-anchored isoform, GAD65. J Biol Chem 1999; 274:37200-9; PMID:10601283; http://dx.doi.org/10.1074/ jbc.274.52.37200 (Pubitemid 30016797)
124. Pleau JM, Fernandez-Saravia F, Esling A, Homo-Delarche F, Dardenne M. Prevention of autoimmune diabetes in nonobese diabetic female mice by treatment with recombinant glutamic acid decarboxylase (GAD 65). Clin Immunol Immunopathol 1995; 76:90-5; PMID:7606872; http://dx.doi.org/10.1006/clin.1995.1092
125. Tisch R, Wang B, Weaver DJ, Liu B, Bui T, Arthos J, et al. Antigen-specific mediated suppression of beta cell autoimmunity by plasmid DNA vaccination. J Immunol 2001; 166:2122-32; PMID:11160264 (Pubitemid 32114703)
126. Tian J, Atkinson MA, Clare-Salzler M, Herschenfeld A, Forsthuber T, Lehmann P V, et al. Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes. J Exp Med 1996; 183:1561-7; PMID:8666914; http://dx.doi.org/10.1084/jem.183.4. 1561 (Pubitemid 26134299)
127. Tisch R, Liblau RS, Yang XD, Liblau P, McDevitt HO. Induction of GAD65-specific regulatory T-cells inhibits ongoing autoimmune diabetes in nonobese diabetic mice. Diabetes 1998; 47:894-9; PMID:9604865; http://dx.doi.org/10.2337/diabetes.47.6.894 (Pubitemid 28255662)
128. Agardh CD, Lynch KF, Palmér M, Link K, Lernmark A. GAD65 vaccination: 5 years of follow-up in a randomised dose-escalating study in adult-onset autoimmune diabetes. Diabetologia 2009; 52:1363-8; PMID:19404608; http://dx.doi.org/10.1007/s00125-009-1371-2
129. Ludvigsson J, Hjorth M, Chéramy M, Axelsson S, Pihl M, Forsander G, et al. Extended evaluation of the safety and efficacy of GAD treatment of children and adolescents with recent-onset type 1 diabetes: a randomised controlled trial. Diabetologia 2011; 54:634-40; PMID:21116604; http://dx.doi.org/10.1007/s00125-010-1988-1
130. Eldor R, Kassem S, Raz I. Immune modulation in type 1 diabetes mellitus using DiaPep277: a short review and update of recent clinical trial results. Diabetes Metab Res Rev 2009; 25:316-20; PMID:19267355; http://dx.doi.org/10. 1002/dmrr.942
131. Elias D, Reshef T, Birk OS, van der Zee R, Walker MD, Cohen IR. Vaccination against autoimmune mouse diabetes with a T-cell epitope of the human 65-kDa heat shock protein. Proc Natl Acad Sci U S A 1991; 88:3088-91; PMID:1707531; http://dx.doi.org/10.1073/pnas.88.8.3088 (Pubitemid 21916564)
132. Elias D, Meilin A, Ablamunits V, Birk OS, Carmi P, Könen-Waisman S, et al. Hsp60 peptide therapy of NOD mouse diabetes induces a Th2 cytokine burst and downregulates autoimmunity to various beta-cell antigens. Diabetes 1997; 46:758-64; PMID:9133541; http://dx.doi.org/10.2337/diabetes.46.5.758 (Pubitemid 27188251)
133. Ablamunits V, Elias D, Reshef T, Cohen IR. Islet T cells secreting IFN-gamma in NOD mouse diabetes: arrest by p277 peptide treatment. J Autoimmun 1998; 11:73-81; PMID:9480725; http://dx.doi.org/10.1006/jaut.1997.0177 (Pubitemid 28080730)
134. Abulafia-Lapid R, Elias D, Raz I, Keren-Zur Y, Atlan H, Cohen IR. T cell proliferative responses of type 1 diabetes patients and healthy individuals to human hsp60 and its peptides. J Autoimmun 1999; 12:121-9; PMID:10047432; http://dx.doi.org/10.1006/jaut.1998.0262 (Pubitemid 29130589)
135. Raz I, Elias D, Avron A, Tamir M, Metzger M, Cohen IR. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet 2001; 358:1749-53; PMID:11734230; http://dx.doi.org/10.1016/S0140-6736(01)06801-5 (Pubitemid 33152998)
136. Raz I, Avron A, Tamir M, Metzger M, Symer L, Eldor R, et al. Treatment of new-onset type 1 diabetes with peptide DiaPep277 is safe and associated with preserved beta-cell function: extension of a randomized, double-blind, phase II trial. Diabetes Metab Res Rev 2007; 23:292-8; PMID:17124720; http://dx.doi.org/10.1002/dmrr.712 (Pubitemid 46851470)
137. Roep BO, Atkinson M, von Herrath M. Satisfaction (not) guaranteed: re-evaluating the use of animal models of type 1 diabetes. Nat Rev Immunol 2004; 4:989-97; PMID:15573133; http://dx.doi.org/10.1038/nri1502 (Pubitemid 39620073)
138. Culina S, Boitard C, Mallone R. Antigen-based immune therapeutics for type 1 diabetes: magic bullets or ordinary blanks? Clin Dev Immunol 2011; 2011:286-248; PMID:21647401; http://dx.doi.org/10.1155/2011/286-248
139. Achenbach P, Barker J, Bonifacio E; Pre-POINT Study Group. Modulating the natural history of type 1 diabetes in children at high genetic risk by mucosal insulin immunization. Curr Diab Rep 2008; 8:87-93; PMID:18445349; http://dx.doi.org/10.1007/s11892-008-0017-y
140. Eisenbarth SC, Colegio OR, O'Connor W, Sutterwala FS, Flavell RA. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008; 453:1122-6; PMID:18496530; http://dx.doi.org/10.1038/nature06939 (Pubitemid 351871731)
141. Bresson D, Fradkin M, Manenkova Y, Rottembourg D, von Herrath M. Genetic-induced variations in the GAD65 T-cell repertoire governs efficacy of anti-CD3/GAD65 combination therapy in new-onset type 1 diabetes. Mol Ther 2010; 18:307-16; PMID:19690518; http://dx.doi.org/10.1038/mt.2009.197
142. Bresson D, Togher L, Rodrigo E, Chen Y, Bluestone JA, Herold KC, et al. Anti-CD3 and nasal proinsulin combination therapy enhances remission from recentonset autoimmune diabetes by inducing Tregs. J Clin Invest 2006; 116:1371-81; PMID:16628253; http://dx.doi.org/10.1172/JCI27191
143. Baeke F, Van Belle TL, Takiishi T, Ding L, Korf H, Laureys J, et al. Low doses of anti-CD3, ciclosporin A and the vitamin D analogue, TX527, synergise to delay recurrence of autoimmune diabetes in an islet-transplanted NOD mouse model of diabetes. Diabetologia 2012; 55:2723-32; PMID:22752077; http://dx.doi.org/10.1007/s00125-012-2630-1
144. Ablamunits V, Henegariu O, Hansen JB, Opare-Addo L, Preston-Hurlburt P, Santamaria P, et al. Synergistic reversal of type 1 diabetes in NOD mice with anti-CD3 and interleukin-1 blockade: evidence of improved immune regulation. Diabetes 2012; 61:145-54; PMID:22043003; http://dx.doi.org/10.2337/db11-1033
145. Rabinovitch A, Suarez-Pinzon WL, Shapiro AM, Rajotte RV, Power R. Combination therapy with sirolimus and interleukin-2 prevents spontaneous and recurrent autoimmune diabetes in NOD mice. Diabetes 2002; 51:638-45; PMID:11872661; http://dx.doi.org/10.2337/diabetes.51.3.638 (Pubitemid 34760170)
146. Long SA, Rieck M, Sanda S, Bollyky JB, Samuels PL, Goland R, et al.; Diabetes TrialNet and the Immune Tolerance Network. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function. Diabetes 2012; 61:2340-8; PMID:22721971; http://dx.doi.org/10.2337/db12-0049
147. Sherry NA, Chen W, Kushner JA, Glandt M, Tang Q, Tsai S, et al. Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells. Endocrinology 2007; 148:5136-44; PMID:17673522; http://dx.doi.org/10.1210/en.2007-0358 (Pubitemid 350012634)
148. Boettler T, von Herrath M. Immunotherapy of type 1 diabetes - how to rationally prioritize combination therapies in T1D. Int Immunopharmacol 2010; 10:1491-5; PMID:20667487; http://dx.doi.org/10.1016/j.intimp.2010.07.008
149. Takiishi T, Korf H, Van Belle TL, Robert S, Grieco FA, Caluwaerts S, et al. Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice. J Clin Invest 2012; 122:1717-25; PMID:22484814; http://dx.doi.org/10.1172/JCI60530 Programme Programme